Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Light, Science & Applications|January 7, 2024
Highly efficient and aberration-free off-plane grating spectrometer and monochromator for EUV-soft X-ray applicationsJie Li, Kui Li, Xiaoshi Zhang, et al.
Medcomm|February 19, 2025
Addition of anti-PD-1 immunotherapy to BRAF inhibitor-based targeted therapy improves real-world survival and delays brain metastases in patients with BRAF<sup>V600</sup>-mutant advanced melanoma: a multicenter cohort studyJunwan Wu, Qiuyue Ding, Qiong Zhang, et al.
Journal for Immunotherapy of Cancer|November 23, 2019
Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibitionXuanye Zhang, Yixin Zhou, Chen Chen, et al.
Cancer Immunology, Immunotherapy : CII|March 2, 2024
Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapyLujun Shen, Hongtong Tan, Juan Nie, et al.
Medcomm|April 27, 2026
Optimal Adjuvant Therapy Selection for Chinese BRAF V600-Mutant Stage III Melanoma: A Multicenter Efficacy Comparison of Targeted Agents, Immunotherapy, and Combinatorial StrategiesRongcheng Zhang, Yao Liang, Jingjing Li, et al.
NPJ Precision Oncology|July 12, 2025
Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II studyZhenlin Hou, Leen Liao, Weiwei Xiao, et al.
Cancer Research|July 4, 2018
<i>PDSS2</i> Deficiency Induces Hepatocarcinogenesis by Decreasing Mitochondrial Respiration and Reprogramming Glucose MetabolismYan Li, Shuhai Lin, Lei Li, et al.
Frontiers in Immunology|October 28, 2022
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 studyLu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Annals of Surgical Oncology|May 12, 2018
Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma PatientsChuanLiang Cui, Bin Lian, Li Zhou, et al.
Translational Oncology|April 14, 2019
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Pageof 9